Achieve Life Sciences
ACHV
28 hedge funds and large institutions have $4.9M invested in Achieve Life Sciences in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 5 closing their positions.
215% more call options, than puts
Call options by funds: $107K | Put options by funds: $34K
0% more funds holding
Funds holding: 28 → 28 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
1.33% less ownership
Funds ownership: 21.92% → 20.59% (-1.3%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
30% less capital invested
Capital invested by funds: $7M → $4.9M (-$2.1M)
Top Buyers
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$184K |
| 2 |
LPL Financial
San Diego,
California
|
+$124K |
| 3 |
Millennium Management
New York
|
+$78.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$40.4K |
| 5 |
HF
HRT Financial
New York
|
+$33.4K |
Top Sellers
| 1 |
6CM
683 Capital Management
New York
|
-$413K |
| 2 |
CC
Clearline Capital
New York
|
-$238K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$112K |
| 4 |
Jane Street
New York
|
-$53K |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$45K |
ACHV Hedge Fund Activity: Q4 2022 in Review
28 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Achieve Life Sciences (ACHV) for Q4 2022, worth a combined $4.9M — down 30% from $7M a quarter earlier.
Fund positioning in ACHV was balanced in Q4 2022: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 8 trimmed.
The largest buyer was Raymond James & Associates, adding an estimated $184K. The largest seller was 683 Capital Management, exiting entirely with an estimated $413K sold.
- 28 institutional investors held Achieve Life Sciences (ACHV) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $4.9M of Achieve Life Sciences stock for Q4 2022, down 30% quarter-over-quarter.
- 5 funds opened new Achieve Life Sciences positions in Q4 2022 and 5 closed out, a net change of 0 holders.
- The largest Achieve Life Sciences buyer in Q4 2022 was Raymond James & Associates, an estimated $184K added.
- The largest Achieve Life Sciences seller in Q4 2022 was 683 Capital Management, an estimated $413K sold.
Based on aggregated 13F filings for Q4 2022.